Mechanisms of Thrombolysis

The pharmacological use of plasminogen activators is associated with symptomatic improvement in patients with coronary artery thrombosis, peripheral arterial occlusions, and thrombosis of the venous system. Based on prospective angiographic studies and planned programs ( 1 – 5 ), thrombolysis is the only approved treatment of acute ischemic stroke ( 6 – 8 ) under limited circumstances. Currently, recombinant tissue plasminogen activator (rt-PA) is licensed in the United States and several other countries for the treatment of ischemic stroke within 3 h of onset ( 6 ). These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.